Shire Plc (SHP) - Financial and Strategic SWOT Analysis Review

August 2018 | 68 pages | ID: S2C4F75EC58EN
GlobalData

Abstracts

Shire Plc (SHP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Shire Plc (Shire) is a biotechnology company that focuses on the research, development, manufacturing, marketing, distribution and sale of novel pharmaceuticals to serve patients with rare diseases and other highly specialized conditions. It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases. The company primarily sells its products through pharmaceutical wholesale distributors and large pharmacies, in both the US and Europe. The company operates along with its subsidiaries and representative offices in Europe, the Americas, Asia Pacific, South Africa and other countries. Shire is headquartered in Dublin, Ireland.

Shire Plc Key Recent Developments

Jul 31,2018: Shire Delivers Q2 2018 Product Sales Growth of 6% and Continued Regulatory and Pipeline Progress
Jul 25,2018: Shire announces Director declaration
Jul 17,2018: argenx receives milestone payment from strategic collaboration with Shire
May 30,2018: Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials
May 02,2018: CENTOGENE Highlights Solutions for Early Diagnosis of Rare Hereditary Disorders at the 2nd Annual Recent Advances in Rare Disease Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Shire Plc - Key Facts
Shire Plc - Key Employees
Shire Plc - Key Employee Biographies
Shire Plc - Major Products and Services
Shire Plc - History
Shire Plc - Company Statement
Shire Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Shire Plc - Business Description
Product Category: Genetic Disease
Overview
Performance
Product Category: Hematology
Overview
Performance
Product Category: Immunology
Overview
Performance
Product Category: Internal Medicine
Overview
Performance
Product Category: Neuroscience
Overview
Performance
Product Category: Oncology
Overview
Performance
Product Category: Ophthalmology
Overview
Performance
Product Category: Royalties and Other Revenues
Overview
Performance
Geographical Segment: Ireland
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: The US
Performance
R&D Overview
Shire Plc - Corporate Strategy
Shire Plc - SWOT Analysis
SWOT Analysis - Overview
Shire Plc - Strengths
Shire Plc - Weaknesses
Shire Plc - Opportunities
Shire Plc - Threats
Shire Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Shire Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 31, 2018: Shire Delivers Q2 2018 Product Sales Growth of 6% and Continued Regulatory and Pipeline Progress
Jul 25, 2018: Shire announces Director declaration
Jul 17, 2018: argenx receives milestone payment from strategic collaboration with Shire
May 30, 2018: Symphogen Further Strengthens its Immuno-Oncology Pipeline by Advancing into Two Additional Clinical Trials
May 02, 2018: CENTOGENE Highlights Solutions for Early Diagnosis of Rare Hereditary Disorders at the 2nd Annual Recent Advances in Rare Disease Conference
Apr 26, 2018: Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018
Mar 22, 2018: Shire Commits to Long-Term Responsibility Goals in 2017 Annual Responsibility Review
Mar 13, 2018: Shire Applies to Cease to be a Reporting Issuer in Canada
Mar 05, 2018: Shire Launches MyPKFi For Advate In U.S
Feb 20, 2018: Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Shire Plc, Key Facts
Shire Plc, Key Employees
Shire Plc, Key Employee Biographies
Shire Plc, Major Products and Services
Shire Plc, History
Shire Plc, Other Locations
Shire Plc, Subsidiaries
Shire Plc, Joint Venture
Shire Plc, Key Competitors
Shire Plc, Ratios based on current share price
Shire Plc, Annual Ratios
Shire Plc, Annual Ratios (Cont.1)
Shire Plc, Annual Ratios (Cont.2)
Shire Plc, Interim Ratios
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Shire Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Shire Plc, Performance Chart (2013 - 2017)
Shire Plc, Ratio Charts
Shire Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Shire Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Supernus Pharmaceuticals Inc
Pfizer Inc
Novo Nordisk AS
Novartis AG
JCR Pharmaceuticals Co Ltd
Ferring International Center SA
Eli Lilly and Co
Bayer AG
Actelion Pharmaceuticals Ltd